Camostat Mesilate Clinical Trials

Size	Price	Qty
10mg	USD 147
50mg	USD 247

Clinical Trials

Multiple clinical trials evaluate Camostat Mesilate as both monotherapy and combination regimens across Phase 1, Phase 2, and Phase 4 development. These studies primarily target COVID-19, SARS-CoV-2 infection, and severe acute respiratory syndrome, alongside associated conditions including diabetes, hypertension, and obesity. Sponsored by academic institutions, comprehensive cancer centers, and pharmaceutical entities, trial statuses across the registry range from completed investigations to terminated and withdrawn studies.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04321096	COMPLETED	Corona Virus Infection	University of Aarhus	2020-04-04	PHASE1; PHASE2
NCT04470544	COMPLETED	Severe Acute Respiratory Syndrome	Alan Bryce	2020-07-28	PHASE2
NCT04338906	WITHDRAWN	COVID	Heinrich-Heine University, Duesseldorf	2020-05	PHASE4
NCT04681430	COMPLETED	Corona Virus Infection; SARS-CoV-2 Infection; SARS-CoV-2 PCR Test Positive; SARS-CoV-2 Acute Respiratory Disease	Heinrich-Heine University, Duesseldorf	2021-01-08	PHASE2
NCT04652765	TERMINATED	Covid19; SARS-CoV Infection; Coronavirus Infection	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	2021-02-03	PHASE1
NCT04530617	TERMINATED	Covid19; Diabetes; Hypertension; Obesity	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran	2020-10-05	PHASE2
NCT04524663	COMPLETED	Covid19	Stanford University	2020-12-19	PHASE2
NCT04583592	COMPLETED	COVID-19	Sagent Pharmaceuticals Inc.	2020-11-09	PHASE2
NCT04353284	COMPLETED	COVID-19	Yale University	2020-06-09	PHASE2
NCT04374019	TERMINATED	COVID; Sars-CoV2	Susanne Arnold	2020-05-01	PHASE2
NCT04455815	Terminated	COVID-19 Infection	Cancer Research UK\|Latus Therapeutics	2020-09-23	Phase 2

(data from https://clinicaltrials.gov, updated on 2025-04-18)

Check the Camostat Mesilate product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Camostat Mesilate acts as a trypsin-like protease inhibitor that potently blocks airway epithelial sodium channel (ENaC) activity with an IC50 of 50 nM, preventing essential proteolytic cleavage of host cell-surface targets. This inhibition disrupts downstream viral membrane fusion and cellular entry pathways, providing a mechanistic basis for its clinical investigation in treating SARS-CoV-2 and COVID-19 infections.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).